Physician profile
Roberto E Estape
NPI 1730264169
$3,990.76
in general payments reported to CMS, 2019-2025
19 companies · $834 in 2025
The $834 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $717 · 2022: $654 · 2023: $1,118 · 2024: $668 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $867.46 | 2021-2025 | Jemperli, Zejula |
| Intuitive Surgical, INC. | $771.48 | 2021-2023 | Da Vinci Surgical System |
| Eisai INC. | $377.60 | 2023-2025 | |
| Momentis Surgical INC. | $355.40 | 2022-2023 | Anovo Surgical System |
| Conmed Corporation | $347.70 | 2024-2025 | Airseal |
| Seagen INC. | $239.96 | 2022-2023 | Tivdak |
| Pfizer INC. | $209.23 | 2024-2025 | |
| Hologic Sales and Service, LLC | $146.26 | 2023-2025 | Coolseal Generator, Acessa Provu System, Myosure Tissue Removal Device |
| Astrazeneca Pharmaceuticals Lp | $132.13 | 2023-2024 | Lynparza |
| Merck Sharp & Dohme LLC | $124.45 | 2021-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $114.71 | 2023-2025 | Veozah |
| Baxter Healthcare | $68.00 | 2022 | |
| Abbvie INC. | $53.24 | 2021 | |
| Coopersurgical, INC. | $51.89 | 2025 | Ally II Ups |
| Boston Scientific Corporation | $37.21 | 2022-2025 | General - Pain Management |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $27.72 | 2022 | |
| Sumitomo Pharma America, INC. | $24.30 | 2025 | Myfembree |
| Springworks Therapeutics, INC. | $22.49 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $19.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Estape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.